1. In conscious rats, intracerebroventricular injection of dopamine resulted in a decrease in blood pressure, whereas injection of metoclopramide, the dopamine antagonist, produced an increase in blood pressure. The central depressor effect of dopamine was attenuated by a subpressor pretreatment with intraventricular metoclopramide, but not by phentolamine.
In t r o d u c t i o n Dopamine may itself be an important neurotransmitter in the peripheral autonomic nervous system as well as in the central nervous system [l] . It has been suggested that the central dopaminergic system participates in the regulation of blood pressure [2-41. In addition, recent studies have revealed that intravenous administration of metoclopramide, the specific dopamine antagonist [5,61, stimulates aldosterone secretion, suggesting that the dopaminergic system is involved in the control of the renin-angiotensinaldosterone axis [7-111. In this study, therefore, we examined the effects of intravenous (i.v.) and intracerebroventricular (i.c.v.) administration of dopamine and metoclopramide on blood pressure, plasma renin activity (PRA) and plasma aldosterone concentration (PA) in conscious rats, and tried to elucidate the role of the central and peripheral dopaminergic systems in the regulation of blood pressure and the renin-angiotensin-aldosterone system in uiuo.
Methods
All experiments were performed in male, conscious, unrestrained Wistar rats, weighing around 300 g. Cannulation of the lateral ventricle, carotid artery and jugular vein was performed under pentobarbital anesthesia (0.2 mmollkg, intraperitoneally) 24 h before the experiment. Arterial blood pressure was recorded continuously through a catheter that had been implanted into the carotid artery with a Nihon Koden MPU-0.5 pressure transducer coupled to a Nihon Koden RM-25 recorder. Drugs. used were dopamine hydrochloride (Sigma), metoclopramide (Fujisawa) and phentolamine (Ciba). These drugs were dissolved or diluted in 0-9%, wlv, NaCl (saline), and the pH and osmotic pressure of the final solutions were adjusted to 7.0 and 300 mosmol/l respectively. Dopamine and metoclopramide were administered i.c.v. or i.v., and the change in mean blood pressure was investigated.
The effect of dopamine on blood pressure was also examined in rats pretreated with metoclopramide or phentolamine. These antagonists were injected 5 min before administration of dopamine. The total volume of injection was always 10 pl in the i.c.v. injection, and 0.3 ml in the i.v. administration. The same volume of saline was injected in control rats. Blood samples were obtained through the catheter implanted in the carotid artery half-an-hour after the i.v. or i.c.v. administration of dopamine, metoclopramide and saline. PRA was measured by the method of Skinner [12]. PA and corticosterone were measured by radioimmunoassay, and plasma sodium and potassium were measured with a flame photometer.
Six rats were examined in each study. Results were expressed as the mean ~S D .
Comparisons were made by Student's t-test.
Results
The initial mean blood pressure of conscious rats tested in these experiments was between 95 and 125 mmHg.
Effect of i.c.v. administration of dopamine and metoclopramide
Injection of dopamine (0.25, 0.5 and 1 pmol/kg) into the cerebral ventricles produced a decrease in blood pressure in a dose-related manner (-2 t 2, -10 t 2 and -21 f 3 mmHg respectively). In contrast, metoclopramide in doses of 170 and 500 nmol/kg increased blood pressure (+ 10 f 3 and +55 f 1 1 mmHg respectively) in a dose-dependent manner. The depressor responses to 0.5 and 1 pmol/kg doses of dopamine were significantly attenuated by i.c.v. preadministration of the subpressor dose (60 nmol/kg) of metoclopramide (-3 f 2 and -1 1 t 4 mmHg respectively; P < O.Ol), but were not affected by that of phentolamine (7 nmol/kg).
Intraventricular injection of dopamine (0.5 pmollkg) resulted in a significant decrease in PRA and PA (P < 0.05), whereas i.c.v. injection of metoclopramide (1 70 nmol/kg) significantly increased PRA and PA (P < 0.02). These compounds did not produce significant changes in plasma sodium, potassium and corticosterone levels ( Table 1) .
Effect of i.v. administration of dopamine and metoclopramide
Intravenous infusion of dopamine (5 nmol min-' kg-I) did not induce significant change in blood pressure, but infusion of 50 nmol of dopamine min-I kg-' resulted in an increase in blood pressure (+15 & 4 mmHg). The i.v. pretreatment with phentolamine (1 a 8 pmollkg) almost completely abolished this pressor effect of dopamine (+ 1 f 2 mmHg). Metoclopramide in a dose of 1.7 pmollkg, when injected i.v., did not show any change in blood pressure, and did not affect the pressor effect of dopamine.
Intravenous administration of the subpressor dose of dopamine (5 nmol min-' kg-') did not induce significant changes in PRA and PA. Metoclopramide (1.7 pmollkg) did not change PRA, whereas it significantly increased PA (P < 0.05). Neither of these compounds produced significant changes in plasma sodium, potassium and corticosterone concentrations ( Table 1) .
Discussion
In conscious rats, i.c.v. injection of dopamine resulted in a decrease in blood pressure whereas [91 observed that intravenous administration of metoclopramide increased PA without changing PRA, plasma cortisol and serum potassium concentrations. Sowers et al. [lo, 111, however, reported that intra-arterial administration of metoclopramide increased both PRA and PA in rats. Our results are consistent with the observations by Carey et al. and Noth et al., suggesting that, even in rats, aldosterone secretion may be under tonic dopaminergic inhibition. In contrast to i.v. administration, i.c.v. injection of metoclopramide increased both PRA and PA, and i.c.v. dopamine decreased both of them. These results indicate that the dopaminergic system in the brain is also involved in the regulation of the renin-angiotensin-aldosterone system. Plasma concentrations of sodium, potassium and corticosterone were not affected by i.c.v. dopamine or metoclopramide. It is therefore suggested that the central dopaminergic system regulates PA through changes in the renin-angiotensin system.
It has been suggested that the dopaminergic system in the brain participates in the regulation of sympathetic nerve activity [4, 16, 171 . The sympathetic nervous system may be involved in changes in PRA and blood pressure induced by i.c.v. dopamine and metoclopramide. Further studies are necessary to clarify the precise nature of central dopaminergic control of the reninangiotensin-aldosterone system and blood pressure.
